- Home
- ANVS vs NRXS Comparison
ANVS vs NRXS Comparison
Compare ANVS & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANVS | NRXS |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.1M | 78.9M |
| IPO Year | 2019 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ANVS | NRXS |
|---|---|---|
| Price | $1.83 | $6.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $13.50 | $13.00 |
| AVG Volume (30 Days) | ★ 587.3K | 88.6K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.39 | 22.13 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $3,569,282.00 |
| Revenue This Year | N/A | $172.91 |
| Revenue Next Year | N/A | $115.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $1.54 | $2.21 |
| 52 Week High | $5.50 | $9.33 |
Technical Indicators
Market Signals| Indicator | ANVS | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 54.69 | 41.67 |
| Support Level | $1.73 | $5.77 |
| Resistance Level | $2.02 | $7.62 |
| Average True Range (ATR) | 0.10 | 0.47 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 72.77 | 47.95 |
Price Performance
Historical ComparisonAbout ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).